The folate receptor (FR) is overexpressed on the vascular side of cancerous cells including those of the breast, ovaries, testes, and cervix. We hypothesized that a folateconjugated immunoglobulin (F-IgG) would bind to the FR that is overexpressed on melanoma tumor cells to target these cells for lysis by natural killer (NK) cells. Folate receptor expression was confirmed in the Mel-39 (human melanoma) cell line by flow cytometry and immunoblot analysis using KB (human oral epithelial) and F01 (human melanoma) as a positive and a negative control, respectively. FR-positive and FR-negative cell lines were treated with F-IgG or control immunoglobulin G in the presence or absence of cytokines to determine NK cell ability to lyse FR-positive cell lines. NK cell activation was significantly upregulated and lysis of Mel 39 tumor cells increased following treatment with F-IgG compared with control immunoglobulin G at all effector : target (E : T) ratios (P < 0.01). This trend further increased by NK cell stimulation with the activating cytokine interleukin-12. NK cell production of cytokines such as interferon-gamma, macrophage inflammatory protein 1α, and regulated on activation normal T-cell expressed and secreted (RANTES) was also significantly increased in response to costimulation with interleukin-12 stimulation and F-IgG-coated Mel 39 target cells compared with controls (P < 0.01). In contrast, F-IgG did not bind to the FR-negative cell line F01 and had no significant effect on NK cell lysis or cytokine production. This research indicates the potential use of F-IgG for its ability to induce an immune response from NK cells against FR-positive melanoma tumor cells, which can be further increased by the addition of cytokines. Melanoma Res 26:329-337 Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
Introduction
Melanoma accounts for the vast majority of skin cancerassociated deaths and its incidence is increasing. Patient outcomes are largely dependent on the stage of disease at the time of initial presentation as over 80% of melanoma patients who present with localized disease can be effectively treated with surgery alone [1] . However, in patients with metastatic melanoma, long-term survival remains at less than 10% [2] . Traditional regimens including dacarbazine, temozolomide, high-dose interleukin-2 (IL-2), and paclitaxel with or without cisplatin or carboplatin have reported only modest response rates (< 20%) [3] . More recently, novel immunotherapeutic and targeted approaches have been developed and used in the treatment of metastatic melanoma, including ipilimumab, a monoclonal antibody directed against CTLA-4, and vemurafenib, a specific inhibitor of signaling by mutated BRAF [3] , but both agents have unique limitations. Phase III trials with ipilimumab reported an overall response rate of less than 20% and showed a high potential for autoimmune toxicity, with immune-related events occurring in 60% of patients [4] . Vemurafenib has led to more impressive response rates (40-50%) in patients with melanoma, but its use is limited to patients with a V600E mutation in the BRAF oncogene [5] . More recently, antibodies that neutralize components of the PD-1/PD-L1 T cell-inhibitory pathway have become available and have shown great promise, especially in combination with other immune checkpoint blockades. A phase I trial of nivolumab and ipilimumab confirmed an objective response of 61% in patients with advanced-stage metastatic melanoma who received the combination versus a response of 11% in patients who received ipilimumab alone [6, 7] . Targeted combination therapies, including BRAF and MEK inhibiters that are approved for the treatment of patients with advanced melanoma carrying the BRAF V600E mutation, result in a high rate of initial tumor responses, with significant survival advantages versus single agents [8] [9] [10] . However, drug resistance and tumor recurrences are still problematic.
These regimens highlight the importance of developing novel therapeutics for the treatment of melanomas that would have relatively low off-target effects.
One potential target for alternative therapeutics in melanoma is the folate receptor (FR). The natural ligand for the FR is folate, a water-soluble B vitamin that functions as a cofactor in various cellular metabolic processes, such as nucleic acid synthesis and protein biosynthesis. However, the common dietary source of folate is obtained through supplemented foods, where the vitamin is present in its oxidized form, known as folic acid [11, 12] . Folic acid is believed to increase cancer cell motility, invasion, metastases, and overall tumor progression [13, 14] . FR expression is normally low and highlevel expression is limited to specific tissues, such as the choroid plexus, epididymis, and kidney. In normal polar epithelial cells, the FR is predominantly located on the nonvascular side of the cell and is thus largely inaccessible to circulating folate [15] . Upon malignant transformation, cell polarity is altered, whereby the FR becomes accessible to circulating folate or folate conjugates. Importantly, the FR is overexpressed in malignant cells, such as cancers of the cervix, breast, testes, uterus, lung, ependymal brain tumors, in blasts of myeloid leukemias, and melanoma [16] [17] [18] [19] [20] . Estimates suggest that roughly one-third of all cancers may show the upregulation of the FR, with metastatic and later-stage cancers associated with increased FR overexpression compared with the FR expression of nonmalignant cells, making the FR an advantageous therapeutic target [21] . High expression of the FR on the surface of tumor cells makes it an attractive therapeutic target. Once a folate conjugate is bound, some of it may be taken up by endocytosis, whereas a fraction may remain engaged with the FR and remain on the cell surface [15] . These parameters are believed to create a favorable toxicity profile for folate-conjugated antitumor compounds [17, 22, 23] .
To eradicate FR-expressing cancer cells, it would be efficacious to engage cells of the innate immune system, such as natural killer (NK) cells. NK cells are bone marrowderived lymphocytes that have the ability to lyse malignant cells with altered expression of major histocompatibility agents. They have high levels of cellular adhesion molecules, express killer cell immunoglobulin receptors (KIRs), and constitutively possess receptors for stimulatory cytokines (e.g. IL-12, IL-15, IL-18). NK cells secrete several antitumor cytokines [e.g. interferon-gamma (IFN-γ), tumor necrosis factor-α, and macrophage inflammatory protein 1α (MIP-1α)] and have the ability to lyse malignant cells using cytolytic granules that contain perforin and granzymes. NK cells also express the FcγRIIIa receptor, an activating receptor that recognizes the constant (Fc) region of IgG. The FcγRIIIa receptor is critical in mediating antibodydependent cellular cytotoxicity (ADCC) against antibody (Ab)-coated targets [24, 25] .
Our group has synthesized a folate-conjugated immunoglobulin (F-IgG) that can bind specifically to FRbearing tumor cell lines. As a critical first step in the development of a novel melanoma therapeutic, the present study was designed to determine the ability of the F-IgG construct to mediate ADCC and cytokine production by NK cells in FR-positive melanoma cell lines. We have previously found that IL-12 can enhance monoclonal antibody therapy and aimed to characterize the antitumor effects of the F-IgG conjugate in combination with this NK cell-activating cytokine [26] .
Materials and methods

F-IgG synthesis
The technique for conjugating folate to macromolecules has been described previously [27, 28] . Folate was reacted with N, N′-dicyclohexylcarbodiimide and N-hydroxysuccinimide (NHS) in dimethyl sulfoxide at stoichiometric molar ratios of 1 : 1 : 1 for 3 h at room temperature. The resultant product was filtered to remove precipitate. The activated folate (F-NHS) was then reacted with IgG (Equitech-Bio Inc., Kerrville, Texas, USA) in pH 8.0 PBS buffer solution at a molar ratio of 12 : 1 for 2 h at room temperature. Following the 2 h incubation, the sample was passed through a PD-10 column equilibrated in PBS (pH 8.0) to remove unreacted F-NHS. For the preparation of fluorescein isothiocyanate (FITC)-labeled F-IgG (F-IgG-FITC) or IgG (IgG-FITC), activated F-NHS was reacted with IgG and FITC in pH 8.0 PBS buffer solution at a molar ratio of 12 : 1 : 5 for 2 h at room temperature. The folate content of the construct was determined by ultraviolet spectrometry at 371 nm and the antibody concentration was determined using the bicinchoninic acid protein assay method. Conjugation reactions performed at IgG-to-folate-NHS ratios of 12 : 1 and 100 : 1 yielded preparations containing an average molar ratio of 2.6 folate molecules per IgG molecule and 9.0 folates per IgG, respectively. As excessive folate conjugation of IgG might adversely affect its effector functions, a lower conjugation level of three folates per IgG was chosen for further study. Unmodified human IgG molecules were used as control immunoglobulin G (C-IgG). Conjugates were stored at 4°C in the dark before use. The molecular weight of the F-IgG construct is ∼ 151 kDa. Our construct showed similar binding and intracellular distribution characteristics in FR-positive cells compared with previously published studies using radiolabeled-conjugate constructs [29, 30] . Binding assays from studies carried out by Henriksen et al. estimated a binding affinity of a folate-conjugated immunoglobulin to have a K D of 10 -9 -10 -10 mol/l, which is comparable with the reported high-affinity binding of folic acid to the FRα (K D ∼ 10 -9 mol/l) [12] . Our group has previously shown that FR binding of F-IgG is evident as early as 30 min after treatment and, following uptake into the cell, was retained on the cell surface for up to 24 h in vitro [31] .
Moreover, in vivo, F-IgG was present at the tumor site for up to 72 h after treatment [31] .
Cell lines
The FR-positive human cell lines KB (human nasopharyngeal epidermal carcinoma, a gift from Dr Philip S. Low, Purdue University, West Lafayette, Indiana, USA), Mel-39 (human melanoma; ATCC, Manassas, Virginia, USA), as well as the FR-negative cell line F01 (human melanoma) were propagated in folate-free RPMI 1640, supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 1% antibiotic-antimycotic (Invitrogen, Grand Island, New York, USA).
Isolation of human NK cells
NK cells were isolated directly from fresh peripheral blood leukopacks (American Red Cross, Columbus, Ohio, USA) by a 30-min incubation with RossetteSep cocktail (Stem Cell Technologies, Vancouver, British Columbia, USA) before Ficoll Hypaque (Sigma, St Louis, Missouri, USA) density gradient centrifugation. Human NK cells were cultured in folate-free RPMI 1640 (purchased from The Cleveland Clinic Media Preparation Service, Cleveland, Ohio, USA) supplemented with 10% heat-inactivated pooled human AB serum (HAB; C-Six Diagnostics, Germantown, Wisconsin, USA) and 1% antibiotic-antimycotic.
Reverse transcription polymerase chain reaction for FR-α expression
Total RNA from Mel 39, KB, and F01 cells was extracted in TRIZOL Reagent using the RNeasy Mini Kit (Qiagen, Valencia, California, USA) following the manufacturer's protocol. RNA was converted into complementary DNA by reverse transcription and used as a template for reversetranscription PCR using FR-α (forward primer, TGGG TGGCTGTAGTAGGGGAG; reverse primer, CAGGG GCACGTTCAGTACC) and FR-β primers (forward primer, ACCAATGCAGTCCCTGGAAGAAGA; reverse primer, AGCTGGGCACTTGTTAACTCCTGA) [32] . The PCR conditions consisted of 95°C for 30 s, followed by 30 cycles of 95°C for 30 s, 58°C for 30 s, and 72°C for 40 s.
Cytotoxicity assays
Purified human NK cells were plated in 96-well V-bottom plates in 10% HAB containing folate-free RPMI 1640 medium supplemented with IL-12 (10 ng/ml) and incubated overnight at 37°C. F-IgG or C-IgG-treated (100 µg/ml) 51 Cr-labeled target cells were added to NK cells at different effector : target (E : T) ratios. Following a 4-h incubation at 37°C, supernatants were harvested for quantification of chromium release. Percentage of lysis was determined as described previously [33] .
In-vitro coculture assay
The FR-positive cell lines, Mel 39 and KB, or the FRnegative cell line, F01, were cultured in the wells of a 96-well flat-bottom culture plate overnight at 37°C as described previously [12, 34] . The culture supernatant was aspirated the following day and wells were treated with 100 µg/ml F-IgG or C-IgG for 1 h at 37°C. After washing off unbound F-IgG or C-IgG, purified NK cells were then added at 2 × 10 5 cells/well in 200 µl of folatefree RPMI containing 10% HAB medium and 10 ng/ml IL-12. Control conditions consisted of NK cells plus tumor cells treated with medium alone, F-IgG or C-IgG alone, or cytokine alone. Culture supernatants were harvested after 48 h and analyzed for IFN-γ, MIP-1α, and RANTES content using an enzyme-linked immunosorbent assay (ELISA). The lower detection limit for all ELISAs was up to 30 pg/ml. All results shown are the mean of triplicate wells SE.
Flow cytometry
The expression of CD69 on the cell surface of NK cells was determined by flow cytometry. Purified NK cells were cultured for 48 h with Mel39, KB, or F01 tumor cells in the same manner as described above for 48 h. Following incubation with antibody-coated tumor cells, NK cells were collected from the coculture plate and incubated on ice for 30 min in flow buffer (5% FBS in PBS) with anti-CD56-APC, a marker for NK cells, and anti-CD69-PE-Cy-7 (BD Biosciences, San Jose, California, USA). Cells were then washed and fixed in 1% formalin. Nonspecific staining by an isotype control Ab was used to determine the percent positive population. Activated NK cells were determined to be CD56 + /CD69 + .
Bioinformatics search
The cancer microarray database and web-based datamining platform Oncomine was used to gather information on the gene expression of folate receptor-α (FOLR1) in a subset of melanoma patients [35] . Data analysis was carried out as fold change comparing normal skin tissues with cutaneous melanoma. Following the expression analysis of FOLR1 from several databases, logtransformed median-centered raw data were downloaded from the Oncomine Platform.
Statistics
These experiments mainly tested whether there were synergistic effects of F-IgG and IL-12 on NK cellmediated ADCC and cytokine production. A Student's t-test and an analysis of variance were utilized for twoway and multiple comparisons, respectively.
Results
The FR is expressed on melanoma tumor cell lines
The KB, Mel-39, and F01 tumor cell lines were analyzed for folate receptor-α (FR-α) expression by reversetranscription PCR. Both cell lines expressed the FR-α transcript, whereas it was not detected in the FR-αnegative F01 cell line (Fig. 1a ). FR protein content was confirmed in the KB and Mel-39 cell lines, as shown by immunoblot analysis (Fig. 1b ). Surface expression of the FR was confirmed in the KB and Mel-39 cell lines, but not in the F01 cell line, as shown by flow cytometry using a F-IgG-FITC-labeled conjugate (Fig. 2) . The FR was not expressed by NK cells (data not shown).
FR-α expression is upregulated in patients with cutaneous melanoma versus normal skin tissues
An Oncomine search of several publically available data sets indicated that FR-α (FOLR1) expression was 22.3-fold upregulated in cutaneous melanoma versus normal skin tissue controls ( Fig. 3) , P = 1.804E − 17. Box plot shows log 2 -transformed mean-centered intensity FOLR1 gene expression of normal controls (n = 26) versus patients with cutaneous melanoma (n = 64) [36] [37] [38] .
NK cells are activated by F-IgG-coated FR-positive melanoma tumor cells
NK cells can interact with antibody-coated target cells because of the fact that they constitutively express an activating, low-affinity receptor for the Fc portion of IgG, known as FcγRIIIa, or CD16. To assess NK cell activation, 48 h coculture experiments were conducted where CD69 upregulation was assessed on NK cells by flow cytometry after exposure to F-IgG-coated tumor cells. CD69 upregulation on NK cells is highly associated with augmented cytotoxicity and a productive antitumor response [39] . There was a significant increase in CD69 expression on NK cells in response to F-IgGcoated KB ( Fig. 4a , P < 0.001) and Mel-39 ( Fig. 4b , P < 0.001) tumor cells, but not the FR-negative F01 cell line (Fig. 4c ). 
F-IgG treatment of FR-positive melanoma tumor results in their lysis by NK cells and is further enhanced by IL-12
The effect of F-IgG on NK cell ADCC of FR-positive tumor targets was examined using Mel-39 ( Fig. 5a ) and KB ( Fig. 5b ) tumor cells as targets. Target cells were labeled with 51 Cr and treated with either C-IgG or F-IgG before use in a standard 4 h ADCC assay with healthy donor human NK cells serving as effectors. There was a significant increase in NK cell-mediated ADCC with F-IgG coating of targets at all effector : target (E : T) ratios in every donor tested compared with C-IgG ( Fig. 5 , P < 0.001). F-IgG treatment did not increase the lysis of the FR-negative cell line F01 (data not shown). Treatment of NK cells with 10 ng/ml of IL-12 (a prototypic NK-activating cytokine) led to a significant increase in F-IgG-mediated cell cytotoxicity of both Mel-39 and KB tumor cells (P < 0.001). The combination of F-IgG and IL-12 resulted in significantly higher tumor cell lysis than either F-IgG or cytokine treatment alone across all E : T ratios.
IL-12 enhances F-IgG-mediated NK cell production of IFN-γ, MIP-1α, and RANTES
Our group has previously reported that costimulation of NK cells by the IL-12R and FcγRIIIa leads to the synergistic production of IFN-γ because of colocalization of these receptors at cell membrane lipid rafts and subsequent increase in signal transduction [34] . We therefore hypothesized that NK cell-activating cytokines would increase NK cell production of IFN-γ following exposure to F-IgG-coated KB tumor cells. An in-vitro assay was performed in which purified NK cells were cocultured with F-IgG-coated FR-positive tumor cells. KB and Mel-39 (FR-positive) and F01 (FR-negative) cells were treated with F-IgG or C-IgG and plated with purified NK cells in the presence or absence of IL-12 (10 ng/ml). After 48 h of coculture, supernatants were harvested and assayed for IFN-γ content. As was observed in the ADCC experiments, F-IgG treatment not only resulted in a significant increase in NK cell IFN-γ secretion, but also showed a highly significant interaction with IL-12 ( Fig. 6a , P < 0.001). The levels of MIP-1α and RANTES were also measured by ELISA as coactivation of the IL-12R and FcγRIIIa on NK cells can stimulate the secretion of these chemokines, in addition to IFN-γ, and have been shown to play a role in coordinating the adaptive immune response [40] . NK cell production of MIP1-α ( Fig. 6b) and RANTES (Fig. 6c ) was significantly increased following treatment with F-IgGcoated tumor cells and IL-12 compared with control conditions (P < 0.001). 
Discussion
In the current study, it was shown that an F-IgG construct can bind to the FR of melanoma tumor cells. F-IgG-treatment of FR-positive melanoma tumor cells led to increased NK cell CD69 expression and NK cellmediated ADCC. Pretreatment of NK cells with IL-12 significantly increased ADCC. Similarly, the addition of IL-12 to the F-IgG stimulus resulted in the robust production of IFN-γ, MIP-1α, and RANTES by NK cells, significantly exceeding the levels observed with either stimulus alone. These results support the investigation of F-IgG and IL-12 in the context of FR-positive melanoma tumor models and as a potential cancer therapeutic. To our knowledge, this is the first evidence of an immunotherapeutic approach designed to exploit the expression of FR in melanoma tumor cells.
The FR functions to concentrate exogenous ligands into the cell cytosol by endocytosis. These endocytic vesicles rapidly become acidified, allowing the FR to release folate into the cell compartment to be used as one of the basic components of cell metabolism and DNA synthesis and repair. It is believed that the overexpression of FR confers a growth advantage by modulating folate uptake from serum, but direct evidence for this mechanism has yet to be provided [41] . FRα, the most widely studied FR isoform, has restricted expression in normal cells, but is highly expressed in various nonmucinous tumors of epithelial origin. Cell culture studies show that expression of the FRα gene (FOLR1) is regulated by extracellular folate depletion, increased homocytstein accumulation, steroid hormone concentrations, interaction with specific transcription factors and cytosolic proteins, and, possibly, epigenetic mutations [12] . The blockade of folate uptake has been shown to decrease tumor cell proliferation, migration, invasion, and tumor burden [12] [13] [14] 42] . Therefore, receptor expression is maintained in the metastatic setting and represents a potential therapeutic target.
The increased expression of the FR on the surface of malignant tumor cells and the high affinity for unidirectional folate transport make exploitation of the FR an advantageous therapeutic target. In melanoma cells, gene expressions of folate receptor alpha (FOLR1), beta (FOLR2), and gamma (FOLR3) are dysregulated compared with normal skin tissues, with a combined 22-fold increase in FOLR1 mRNA levels in cutaneous malignant melanoma [36] [37] [38] . This discovery suggests that an FRdirected therapy could selectively target malignant cells and avoid healthy tissues. The FR has been utilized previously for the investigational delivery of cytotoxic drugs, radiopharmaceuticals, nanoparticles, liposomes, and immunotherapy in other tumor settings [17, 43] .
Recently, there has been evidence that a folateconjugated agent could be involved in the induction of autophagic cell death in melanoma cells. A folateconjugated methyl-β-cyclodextrin showed cytotoxic effects against FRα-positive melanoma tumor cells through FR-α-mediated endocytosis by eliciting the formation of autophagosomes [44] . Furthermore, encapsulation of vincristine into folic acid-conjugated PEGylated liposomes overcame multidrug resistance to chemotherapy in KBv200 cells [45] . A bispecific monoclonal antibody directed to the CD3 molecule on T lymphocytes and to the folate receptor on ovarian carcinoma cells showed clinical efficacy as three of 19 patients showed a complete response, three achieved a partial response, and seven had stable disease [46] . These data, along with the present study, support the development of FR-directed therapeutic immunoconjugates.
Targeting tumors with antibodies constitutes an attractive therapeutic strategy as these molecules are highly specific for their target and can function through various mechanisms against cancer cells, such as signaling to induce tumor cell growth arrest, inducing apoptosis, and promoting immune cell-mediated cytotoxicity and complement activation. Antibodies coupled to toxins, radionuclides, or cytokines are expected to specifically deliver those toxic payloads to cancer cells. Antibodies may also act as immunogens or engage Fc receptors on antigen presenting cells such as dendritic cells to promote antigen presentation and induction of adaptive immune responses against cancer cells. Several efforts to exploit mAb therapy in the context of melanoma have been made aiming to enhance T cell activation, target vascular endothelial growth factor, or highlight the expression of high-molecular-weight melanoma-associated antigen [47] [48] [49] [50] . The present approach uses the affinity of folate for the FR to coat the cancer cell with IgG molecules.
We have shown that NK cell recognition of F-IgG-coated FR-positive melanoma tumor cells leads to an increase in cytoxocity and cytokine production. NK cells exert their effector functions by multiple mechanisms, either through the direct cytolysis of transformed cells by the release of perforin and granzyme B through antibodydependent cytoxicity or by the secretion of cytokines and chemokines that can influence the host's immune response. We have previously shown that the dual engagement of NK cell CD16 and cytokine receptors by cytokines such as IL-2, IL-12, or IL-21 results in synergistic ADCC and IFN-γ production in solid tumors [26, 34, [51] [52] [53] . Here, robust and synergistic increases in ADCC and the levels of IFN-γ, MIP-1α, and RANTES were observed in response to F-IgG and IL-12 over either stimulus alone in melanoma tumor cells. Thus, the coadministration of IL-12 and the F-IgG construct could be expected to promote an NK-dependent antitumor response in the clinical setting and offers promise in situations where other targeted agents have failed. Given the recent success of immune checkpoint inhibitors as a systemic therapeutic agent for the treatment of metastatic melanoma, the use of anti-PD-1/PD-L1 or anti-CTLA4 therapy could potentially enhance the immunologic activity of F-IgG. In addition, the fusion of cytokines to antibodies is a promising strategy that would limit the toxicities observed with systemic administration of immunostimulatory cytokines. An F-IgG : IL-12 fusion is under consideration.
In summary, it has been shown that F-IgG complexes can be utilized to specifically enhance the immune response by NK cells against FR-positive melanoma tumor cells in vitro. Furthermore, it was shown that there is a large increase in FOLR1 expression in cutaneous melanoma versus normal controls. Treatment of NK cells with the immune stimulatory cytokine IL-12 significantly augmented their ability to lyse FR-targeted tumor cells and secrete immune-modulating cytokines. Thus, F-IgG and IL-12 can target NK cells to melanoma tumor cells by means of the FR.
